Transdermally Deliverable Opioid Prodrugs, Abuse-Resistant Compositions and Methods of Using Opioid Prodrugs
AssigneeAllTranz Inc.
InventorsAudra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammel, Jeffrey Lynn Howard
Life of this patent
Estimating the term…
Abstract
Described herein are opioid prodrugs, methods of making opioid prodrugs, formulations comprising opioid prodrugs, and methods of using opioid prodrugs. One embodiment described herein relates to the transdermal administration of a buprenorphine prodrug in an abuse-resistant formulation for treating and preventing diseases and/or disorders.
Claims22
A compound having the formula:
- wherein R1 is selected from the group consisting of oxygenated alkyl carbonate, and oxygenated ester, wherein the oxygenated ester does not terminate in an —OH group.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A prodrug of buprenorphine having an in vitro transdermal flux enhancement of greater than one relative to buprenorphine.
A prodrug of buprenorphine having an in vitro transdermal flux (nmol/cm2/hr) greater than buprenorphine.
A prodrug of buprenorphine having a twenty-four hour cumulative amount (nmol) of in vitro transdermal permeation greater than buprenorphine.
Dependencies are inferred from the claim text.